BRPI0921341A2 - tratamento de leucemia linfoblástica aguda pediátrica - Google Patents

tratamento de leucemia linfoblástica aguda pediátrica

Info

Publication number
BRPI0921341A2
BRPI0921341A2 BRPI0921341A BRPI0921341A BRPI0921341A2 BR PI0921341 A2 BRPI0921341 A2 BR PI0921341A2 BR PI0921341 A BRPI0921341 A BR PI0921341A BR PI0921341 A BRPI0921341 A BR PI0921341A BR PI0921341 A2 BRPI0921341 A2 BR PI0921341A2
Authority
BR
Brazil
Prior art keywords
treatment
lymphoblastic leukemia
acute lymphoblastic
pediatric acute
pediatric
Prior art date
Application number
BRPI0921341A
Other languages
English (en)
Portuguese (pt)
Inventor
Gerhard Zugmaier
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BRPI0921341A2 publication Critical patent/BRPI0921341A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0921341A 2008-11-07 2009-11-06 tratamento de leucemia linfoblástica aguda pediátrica BRPI0921341A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
BRPI0921341A2 true BRPI0921341A2 (pt) 2016-04-26

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921341A BRPI0921341A2 (pt) 2008-11-07 2009-11-06 tratamento de leucemia linfoblástica aguda pediátrica

Country Status (27)

Country Link
US (2) US20110262440A1 (enExample)
EP (4) EP3594237A1 (enExample)
JP (2) JP5798036B2 (enExample)
KR (1) KR101695329B1 (enExample)
CN (2) CN106390114A (enExample)
AU (1) AU2009313039B2 (enExample)
BR (1) BRPI0921341A2 (enExample)
CA (1) CA2742242C (enExample)
CY (3) CY1116160T1 (enExample)
DK (3) DK2344539T3 (enExample)
ES (3) ES2662929T3 (enExample)
HK (1) HK1255590B (enExample)
HR (3) HRP20150400T1 (enExample)
HU (3) HUE025452T2 (enExample)
IL (1) IL212651A (enExample)
LT (2) LT2918604T (enExample)
MX (1) MX2011002931A (enExample)
NO (1) NO2918604T3 (enExample)
NZ (1) NZ591312A (enExample)
PL (3) PL2344539T3 (enExample)
PT (3) PT3330293T (enExample)
RS (3) RS56989B1 (enExample)
RU (3) RU2536933C2 (enExample)
SG (1) SG195549A1 (enExample)
SI (3) SI2344539T1 (enExample)
SM (3) SMT201900546T1 (enExample)
WO (1) WO2010052013A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP3594237A1 (en) * 2008-11-07 2020-01-15 Amgen Research (Munich) GmbH Treatment of pediatric acute lymphoblastic leukemia
WO2010079339A2 (en) * 2009-01-09 2010-07-15 Oxford Biomedica (Uk) Limited Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015010740B1 (pt) * 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PL3531133T3 (pl) 2014-05-30 2024-01-29 Amgen Research (Munich) Gmbh Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b
EP3175244A4 (en) * 2014-07-30 2018-06-13 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
LT3699198T (lt) 2014-11-17 2025-05-12 Regeneron Pharmaceuticals, Inc. Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną
US10988533B2 (en) 2015-02-05 2021-04-27 Unm Rainforest Innovations Anti-pre-BCR antagonists and methods
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
LT3298042T (lt) 2015-05-20 2025-02-10 Amgen Research (Munich) Gmbh B-ląstelių naikinimas kaip diagnostinis žymuo
EP3394102A1 (en) * 2015-12-22 2018-10-31 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
MX2018011169A (es) * 2016-03-14 2018-12-06 Millennium Pharm Inc Metodo para prevenir la enfermedad del injerto contra huesped.
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
UY37726A (es) * 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
FI3844189T3 (fi) 2018-08-31 2025-03-05 Regeneron Pharma Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää
KR20210122268A (ko) * 2019-01-30 2021-10-08 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 암 항원을 표적화하는 dna-인코딩된 이중특이적 t-세포 인게이저 및 암 치료에서 사용 방법
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL305188A (en) 2021-02-16 2023-10-01 Childrens Health Care D/B/A Childrens Minnesota Methods for treating B-ALL by administering a pre-BCR complex antagonist
IL311714A (en) 2021-10-15 2024-05-01 Amgen Res Munich Gmbh Subcutaneous administration of antibodies that engage CD19-binding T cells
WO2025101672A1 (en) 2023-11-06 2025-05-15 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
RU2005141512A (ru) * 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
PL1976886T3 (pl) * 2005-12-16 2015-06-30 Amgen Res Munich Gmbh Środki i metody do leczenia chorób nowotworowych
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
EP3594237A1 (en) * 2008-11-07 2020-01-15 Amgen Research (Munich) GmbH Treatment of pediatric acute lymphoblastic leukemia
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
CA2936120A1 (en) * 2009-01-19 2010-07-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
AU2010311559B2 (en) * 2009-10-27 2016-07-07 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody

Also Published As

Publication number Publication date
DK2918604T3 (en) 2018-03-19
CY1122428T1 (el) 2021-01-27
PT2918604T (pt) 2018-03-02
US20230235053A1 (en) 2023-07-27
MX2011002931A (es) 2011-04-11
RS56989B1 (sr) 2018-05-31
CA2742242C (en) 2023-01-10
PL3330293T3 (pl) 2020-02-28
DK2344539T3 (en) 2015-05-04
PL2918604T3 (pl) 2018-05-30
HK1255590B (en) 2020-07-10
SG195549A1 (en) 2013-12-30
SMT201900546T1 (it) 2019-11-13
PT2344539E (pt) 2015-04-01
CN102209729B (zh) 2016-05-25
RU2736802C2 (ru) 2020-11-20
HRP20191715T1 (hr) 2019-12-13
RU2014141180A (ru) 2016-05-10
NZ591312A (en) 2012-09-28
EP2344539A1 (en) 2011-07-20
AU2009313039B2 (en) 2015-06-18
RS53980B1 (sr) 2015-10-30
HUE036922T2 (hu) 2018-08-28
SMT201800149T1 (it) 2018-05-02
EP3594237A1 (en) 2020-01-15
SI2918604T1 (en) 2018-04-30
ES2662929T3 (es) 2018-04-10
RU2018144313A (ru) 2020-06-15
RU2014141180A3 (enExample) 2018-06-09
CA2742242A1 (en) 2010-05-14
RS59348B1 (sr) 2019-10-31
SI2344539T1 (sl) 2015-06-30
DK3330293T3 (da) 2019-10-07
RU2677324C2 (ru) 2019-01-16
LT3330293T (lt) 2019-10-10
CY1120022T1 (el) 2018-12-12
JP6130451B2 (ja) 2017-05-17
JP2015232023A (ja) 2015-12-24
NO2918604T3 (enExample) 2018-05-19
PL2344539T3 (pl) 2015-07-31
EP3330293A1 (en) 2018-06-06
KR20110091669A (ko) 2011-08-12
EP3330293B1 (en) 2019-07-24
EP2344539B1 (en) 2015-02-11
HRP20150400T1 (hr) 2015-05-08
SI3330293T1 (sl) 2019-10-30
JP2012508163A (ja) 2012-04-05
EP2918604A1 (en) 2015-09-16
AU2009313039A1 (en) 2010-05-14
ES2748126T3 (es) 2020-03-13
HRP20180426T1 (hr) 2018-04-20
US20110262440A1 (en) 2011-10-27
ES2535257T3 (es) 2015-05-07
WO2010052013A1 (en) 2010-05-14
PT3330293T (pt) 2019-10-18
EP2918604B1 (en) 2017-12-20
RU2536933C2 (ru) 2014-12-27
LT2918604T (lt) 2018-03-26
CN106390114A (zh) 2017-02-15
SMT201500104B (it) 2015-07-09
IL212651A0 (en) 2011-07-31
HUE046222T2 (hu) 2020-02-28
CY1116160T1 (el) 2017-02-08
KR101695329B1 (ko) 2017-01-23
IL212651A (en) 2015-03-31
HK1215258A1 (en) 2016-08-19
HK1158667A1 (en) 2012-07-20
HUE025452T2 (en) 2016-05-30
RU2011122827A (ru) 2012-12-20
RU2018144313A3 (enExample) 2020-06-15
JP5798036B2 (ja) 2015-10-21
CN102209729A (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
BRPI0921341A2 (pt) tratamento de leucemia linfoblástica aguda pediátrica
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
BRPI0910854A2 (pt) métodos de tratamento
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
BRPI0917567A2 (pt) tratamento de doença respiratória
DK2330887T3 (da) Behandlingsindretning
BRPI0912683A2 (pt) tratamento de tumores metastáticos
DK2173831T3 (da) Brøndbehandling
DE502008000740D1 (de) Rollosystem
EP3381471C0 (en) PAIN TREATMENT
EP2368499A4 (en) TREATMENT INSTRUMENT
HRP20150373T1 (xx) Dijagnostiäśke metode b-staniäśnog limfoma
HUE038563T2 (hu) Rák kezelési eljárás
LTPA2016019I1 (lt) Išsėtinės sklerozės (MS) gydymas kampatu-1H
HRP20160577T1 (hr) Liječenje osteoartritisa
EP2319442A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE
EP2308405A4 (en) HIGH FREQUENCY TREATMENT INSTRUMENT
DE602007013310D1 (de) Hochfrequenzbehandlungsinstrument
BRPI0815051A2 (pt) Tratamento de tumores pediátricos
EP2327367A4 (en) INSTRUMENT FOR ENDOSCOPIC TREATMENT
BRPI0922216A2 (pt) tratamento para glomerulonefrite
GB0723100D0 (en) Treatment of HFnEF
BRPI0815772A2 (pt) Tratamento de câncer de pulmão
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AMGEM RESEARCH (MUICH) GMBH (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]